Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands
This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified α1-α2 domains of NKG2D ligands. This application further relates to modified α1-α2 domains of NKG2D ligands attached to polypeptides, in some embodiments antibodies or fragments of antibodies. This application further relates to antigen-binding peptides derived from light and heavy chain antibody variable domains, which contain two linker regions and a split variable domain.
1. A non-natural, modified α1-α2 domain molecule from a human native NKG2D ligand molecule,
wherein said domain molecule comprises an amino acid sequence having at least 95% identity to the entirety of SEQ ID NO: 16,
and wherein in said amino acid sequence having at least 95% identity to the entirety of SEQ ID NO: 16, one or more of the positions corresponding to positions 80, 151, 152, and 153 of SEQ ID NO: 16 have a different amino acid residue as compared to SEQ ID NO: 16.
2. The modified α1-α2 domain molecule of claim 1 , wherein in said amino acid sequence having at least 95% identity to the entirety of SEQ ID NO: 16, the amino acid residue at the position corresponding to the cysteine at position 8 of SEQ ID NO: 16 is a serine.
3. The modified α1-α2 domain molecule of claim 1 , wherein said amino acid sequence having at least 95% identity to the entirety of SEQ ID NO: 16 has at least one of the following features:
the amino acid at the position corresponding to position 80 of SEQ ID NO: 16 is a L, W, V, F, I, S, A, E, P, or T residue;
the amino acid at the position corresponding to position 151 of SEQ ID NO: 16 is a D, E, Q, K, N, R or T residue;
the amino acid at the position corresponding to position 152 of SEQ ID NO: 16 is a L or W residue; and
the amino acid at the position corresponding to position 153 of SEQ ID NO: 16 is a E, K, G, or P residue.
4. The modified α1-α2 domain molecule of claim 1 , which is attached to an immunogen.
5. The modified α1-α2 domain molecule of claim 1 , which comprises the amino acid sequence of SEQ ID NO: 85 but in which the cysteine at position 8 is replaced by serine.
6. The modified α1-α2 domain molecule of claim 1 , which comprises the amino acid sequence of SEQ ID NO: 85.
7. The modified α1-α2 domain molecule of claim 1 , further comprising an attached heterologous molecule.
8. The modified α1-α2 domain molecule of claim 7 , wherein the heterologous molecule is a heterologous peptide.
9. The modified α1-α2 domain molecule of claim 8 , wherein the attached heterologous peptide is an antibody, antibody light chain, antibody heavy chain, or fragment thereof.